Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in AML
NCT05345938Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 28 days and Complete Remission. Started Jun 2022; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05345938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345938.